On May 16, 2023, the US Court of Appeals for the Second Circuit affirmed the Southern District of New York’s order dismissing an action brought by investors of AstraZeneca PLC (AstraZeneca) attempting to hold the company...more
6/19/2023
/ AstraZeneca ,
Class Action ,
Clinical Trials ,
Dismissals ,
Material Misstatements ,
Pharmaceutical Industry ,
Popular ,
Rule 10b-5 ,
Securities Exchange Act ,
Securities Litigation ,
Shareholder Litigation ,
Vaccinations
On March 22, 2023, the US Securities and Exchange Commission (SEC) filed a complaint in US District Court for the Southern District of New York against Justin Sun, the owner of BitTorrent, Inc., a file-sharing platform; three...more
4/25/2023
/ Asset Tokens ,
Celebrity Endorsements ,
Class Action ,
Conflicts of Interest ,
Corporate Governance ,
Cryptoassets ,
Delaware General Corporation Law ,
Endorsements ,
Enforcement Actions ,
Exculpatory Clauses ,
Fiduciary Duty ,
Life Sciences ,
Popular ,
Revlon Standard ,
Securities Act of 1933 ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act ,
Securities Fraud ,
Securities Violations ,
Share Classes ,
Share Price ,
Shareholder Votes
On September 27, 2022, U.S. District Judge Kevin McNulty of the District of New Jersey dismissed a consolidated derivative action allegedly brought on behalf of Cognizant Technology Solutions Corporation against certain...more
11/3/2022
/ Administrative Hearings ,
Caremark claim ,
Class Action ,
Compliance ,
Constitutional Challenges ,
Cooperation ,
Department of Justice (DOJ) ,
Derivative Suit ,
Foreign Corrupt Practices Act (FCPA) ,
Indictments ,
Non-Fungible Tokens (NFTs) ,
Popular ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act ,
Securities Litigation ,
Shareholder Litigation ,
Shareholders
On July 12, 2022, Twitter, Inc. brought a civil action in the Delaware Court of Chancery against Elon Musk, the co-founder and CEO of Tesla Motors, Inc., for breach of contract in an attempt to force Musk to complete his...more
7/28/2022
/ Acquisitions ,
Attorney-Client Privilege ,
Breach of Contract ,
Class Action ,
Criminal Convictions ,
Cryptoassets ,
Cryptocurrency ,
Discovery Disputes ,
Elon Musk ,
Gaming ,
Insider Trading ,
Merger Agreements ,
Securities ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act ,
Securities Fraud ,
Specific Performance ,
Spoofing ,
Twitter
On June 3, 2022, the Delaware Court of Chancery dismissed the final two counts in an action against California biotech firm Vaxart, Inc., finding that plaintiffs failed to adequately allege that certain non-public information...more
6/16/2022
/ Amazon ,
Books & Records ,
Class Action ,
Class Certification ,
Dismissals ,
Fraud-on-the-Market ,
Incentive Compensation ,
Leave to Amend ,
Material Nonpublic Information ,
Pharmaceutical Industry ,
Rebuttable Presumptions ,
Securities Fraud ,
Shareholder Rights ,
Shareholders ,
Stock Prices ,
Vaccinations
Delaware Chancery Court Dismisses Cigna Derivative Suit Over Failed Anthem Merger; The PCAOB Sanctions Former KPMG Vice Chair Of Audit For Failure To Supervise Senior Members Of KPMG's Audit Practice; Ninth Circuit Affirms...more
4/21/2022
/ Anthem Insurance ,
Board of Directors ,
Breach of Contract ,
Breach of Duty ,
CEOs ,
CIGNA ,
Civil Monetary Penalty ,
Class Action ,
Coronavirus/COVID-19 ,
Derivative Suit ,
Disgorgement ,
Dismissals ,
False Statements ,
Fiduciary Duty ,
KPMG ,
Material Misstatements ,
Mergers ,
Misleading Statements ,
Omissions ,
PCAOB ,
Publicly-Traded Companies ,
Putative Class Actions ,
Sanctions ,
Sarbanes-Oxley ,
Scienter ,
Securities Exchange Act of 1934 ,
Securities Litigation ,
Securities Transactions ,
Securities Violations ,
Shareholders ,
Short-Swing Trading
Delaware Federal Court Dismisses Shareholder Derivative Suit Concerning Lack of Board Diversity; California Federal Court Dismisses Shareholder Class Action Against Sorrento Therapeutics Regarding COVID-19 Treatment; Delaware...more
12/23/2021
/ Board of Directors ,
Cannabis-Related Businesses (CRBs) ,
Class Action ,
Coronavirus/COVID-19 ,
Derivative Suit ,
Discovery ,
Discovery Violations ,
Dismissals ,
Diversity ,
False Statements ,
Investment Fraud ,
Investors ,
Misleading Statements ,
Misrepresentation ,
Pharmaceutical Industry ,
Popular ,
Putative Class Actions ,
Rule 10b-5 ,
Scienter ,
Securities Exchange Act of 1934 ,
Securities Violations ,
Shareholder Litigation ,
Shareholders